---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-053285"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T07:45:30.209948+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vyome Q1 2025 net loss widens to $294K; going concern raises risk for ReShape merger

## Summary
- Vyome revenue rose to $198.6K (Q1 2025) from $77.0K YoY, but net loss widened from $127K to $294K.
- Current liabilities exceed current assets by $5.2M; substantial doubt about Vyome's going concern is disclosed.
- Convertible debt current portion stands at $3.84M; company relies on continued note issuances for funding.
- Pro forma combined financials filed as part of ReShape's S-3 shelf registration for the pending merger.
- Vyome plans FDA meeting for VT-1953 pivotal trial in Q3 2025; has Phase III-ready acne program.

## SEC filing metadata
- accession: 0001104659-25-053285
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465925053285/0001104659-25-053285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465925053285/tm2515903d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-053285
- JSON: https://secwatch.observer/filing/0001104659-25-053285.json
- Plain text: https://secwatch.observer/filing/0001104659-25-053285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.